JO3048B1 - مشتقات متاستين واستخدامها - Google Patents
مشتقات متاستين واستخدامهاInfo
- Publication number
- JO3048B1 JO3048B1 JOP/2007/0448A JOP20070448A JO3048B1 JO 3048 B1 JO3048 B1 JO 3048B1 JO P20070448 A JOP20070448 A JO P20070448A JO 3048 B1 JO3048 B1 JO 3048B1
- Authority
- JO
- Jordan
- Prior art keywords
- suppressing activity
- activity
- hormone secretion
- metastin
- metastin derivatives
- Prior art date
Links
- KAHDONZOCXSKII-NJVVDGNHSA-N kisspeptin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)O)C1=CN=CN1 KAHDONZOCXSKII-NJVVDGNHSA-N 0.000 title abstract 5
- 230000000694 effects Effects 0.000 abstract 6
- 230000028327 secretion Effects 0.000 abstract 4
- 206010027476 Metastases Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 230000005907 cancer growth Effects 0.000 abstract 2
- 239000003163 gonadal steroid hormone Substances 0.000 abstract 2
- 230000001456 gonadotroph Effects 0.000 abstract 2
- 239000005556 hormone Substances 0.000 abstract 2
- 229940088597 hormone Drugs 0.000 abstract 2
- 230000009401 metastasis Effects 0.000 abstract 2
- 230000004936 stimulating effect Effects 0.000 abstract 2
- 102000013599 Kisspeptins Human genes 0.000 abstract 1
- 108010012048 Kisspeptins Proteins 0.000 abstract 1
- 230000004071 biological effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 238000001879 gelation Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
- C07K14/4703—Inhibitors; Suppressors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Reproductive Health (AREA)
- Zoology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Gynecology & Obstetrics (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Obesity (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Pregnancy & Childbirth (AREA)
Abstract
يتعلق الاختراع الحالي بمشتقات متاستين (metastin) ثابتة لها انشطة حيوية ممتازة (نشاط لكبح السرطان, نشاط كبح نمو السرطان، نشاط يحث افراز هرمون انتحاء للغدد التناسلية، نشاط يحث افراز الهرمون الجنسي، الخ). بتعديل الاحماض الامينية(amino acids) التي تشكل المتاستين (metastin) مع احماض امينية (amino acids) خاصة، فانه يظهر بصورة غير متوقعة ثباتا وقابلية ذوبان محسنة في الدم، انخفاض الميل الى تكوين هلام، تحسنا في الحركة الدوائية، ويظهر اضافيا نشاطا ممتازا كابحا لانتشار السرطان او كابحا لنمو السرطان. ان مشتقات المتاستين (metastin) بصورة غير متوقعة لها تأثير كابح لافراز هرمون انتحاء للغدد التناسلية، تأثير كابح لافراز الهرمون الجنسي، الخ.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006290536 | 2006-10-25 | ||
| JP2007021387 | 2007-01-31 | ||
| JP2007221911 | 2007-08-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JO3048B1 true JO3048B1 (ar) | 2016-09-05 |
Family
ID=38925530
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JOP/2007/0448A JO3048B1 (ar) | 2006-10-25 | 2007-10-23 | مشتقات متاستين واستخدامها |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US7786083B2 (ar) |
| EP (1) | EP2081955B1 (ar) |
| JP (2) | JP2010507565A (ar) |
| KR (1) | KR101424306B1 (ar) |
| AR (1) | AR063367A1 (ar) |
| AU (1) | AU2007309969B2 (ar) |
| BR (1) | BRPI0717441B8 (ar) |
| CA (1) | CA2667537C (ar) |
| CL (1) | CL2007003053A1 (ar) |
| CR (1) | CR10799A (ar) |
| CY (1) | CY1116627T1 (ar) |
| DK (1) | DK2081955T3 (ar) |
| EC (1) | ECSP099279A (ar) |
| ES (1) | ES2539430T3 (ar) |
| GE (1) | GEP20125568B (ar) |
| HR (1) | HRP20150819T1 (ar) |
| HU (1) | HUE025291T2 (ar) |
| IL (1) | IL198046A (ar) |
| JO (1) | JO3048B1 (ar) |
| MA (1) | MA30887B1 (ar) |
| ME (1) | ME00786B (ar) |
| MX (1) | MX2009004148A (ar) |
| MY (1) | MY145975A (ar) |
| NO (1) | NO341584B1 (ar) |
| NZ (1) | NZ576375A (ar) |
| PE (1) | PE20081469A1 (ar) |
| PL (1) | PL2081955T3 (ar) |
| PT (1) | PT2081955E (ar) |
| RS (1) | RS54083B1 (ar) |
| SI (1) | SI2081955T1 (ar) |
| TN (1) | TN2009000140A1 (ar) |
| TW (1) | TWI404726B (ar) |
| WO (1) | WO2008050897A1 (ar) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003292696A1 (en) | 2002-12-26 | 2004-08-10 | Takeda Pharmaceutical Company Limited | Metastin derivative and use thereof |
| MXPA06014206A (es) | 2004-06-25 | 2007-02-14 | Takeda Pharmaceutical | Derivados de metastina y uso de los mismos. |
| TWI386417B (zh) | 2005-12-22 | 2013-02-21 | Takeda Pharmaceutical | 轉移抑素衍生物及其用途 |
| US20090093615A1 (en) * | 2005-12-22 | 2009-04-09 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US20090099334A1 (en) * | 2005-12-22 | 2009-04-16 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US8183212B2 (en) * | 2006-04-26 | 2012-05-22 | Kyoto University | Compound having GPR54 agonistic activity |
| TWI404726B (zh) | 2006-10-25 | 2013-08-11 | Takeda Pharmaceutical | 腫瘤轉移抑制素衍生物及其用途 |
| US8110639B2 (en) * | 2006-11-17 | 2012-02-07 | Solvay Advanced Polymers, L.L.C. | Transparent and flame retardant polysulfone compositions |
| EP2277900A4 (en) * | 2008-04-24 | 2011-08-03 | Takeda Pharmaceutical | METASTINE DERIVATIVE AND ITS USE |
| EP2275433B1 (en) * | 2008-04-30 | 2017-06-07 | Kyoto University | Metastin derivative and use thereof |
| US20110212890A1 (en) * | 2008-07-30 | 2011-09-01 | Takeda Pharmaceutical Company Limited | Metastin derivative and use thereof |
| US8716228B2 (en) | 2009-05-27 | 2014-05-06 | Yeda Research And Development Co. Ltd. | GPR54 agonists or antagonists for treatment of diseases presenting behavioral abnormalities |
| BR112012032544A2 (pt) * | 2010-06-25 | 2016-10-11 | Takeda Pharmaceutical | formulação de liberação prolongada, uso de um composto, e, método para produzir a formulação de liberação prolongada. |
| US9127038B2 (en) | 2011-08-04 | 2015-09-08 | Merck Sharp & Dohme Corp. | Kisspeptide-pentasaccharide conjugates |
| JP6612742B2 (ja) * | 2013-06-12 | 2019-11-27 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | 関節症の処置のためのヒドロキシエチレン誘導体 |
| US10220069B2 (en) * | 2014-01-22 | 2019-03-05 | The Johns Hopkins University | Compositions and methods for treating diabetes |
| JP6253146B2 (ja) * | 2014-02-04 | 2017-12-27 | 国立大学法人山口大学 | 新規なペプチド誘導体及びこれを含有する医薬 |
| WO2016125172A1 (en) * | 2015-02-08 | 2016-08-11 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Peptides for the treatment of malignant proliferative diseases |
| CN109206481B (zh) | 2017-07-05 | 2023-08-18 | 尚华医药科技(江西)有限公司 | 一种肽类化合物、其应用及含其的组合物 |
| TWI795462B (zh) * | 2017-11-17 | 2023-03-11 | 日商鹽野義製藥股份有限公司 | 光安定性及溶出性優異的醫藥製劑 |
| EP4132559A4 (en) * | 2020-04-08 | 2024-06-12 | Rutgers, the State University of New Jersey | MODIFIED KISSPEPTIN RECEPTOR AGONISTS FOR FATTY LIVER STEATOSIS |
| WO2025217074A1 (en) * | 2024-04-08 | 2025-10-16 | Radionetics Oncology, Inc. | Kisspeptin receptor (kiss1r) targeted therapeutics and uses thereof |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL74827A (en) | 1984-05-21 | 1989-06-30 | Salk Inst For Biological Studi | Peptides active as gnrh antagonists and pharmaceutical compositions containing them |
| MX9100717A (es) | 1990-08-24 | 1992-04-01 | Syntex Inc | Antagonistas de la bradiquinina |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| JPH09169735A (ja) | 1995-10-19 | 1997-06-30 | Takeda Chem Ind Ltd | キノリン誘導体、その製造法および用途 |
| AU7333496A (en) | 1995-10-19 | 1997-05-07 | Takeda Chemical Industries Ltd. | Quinoline derivatives as gnrh antagonists |
| AU2382097A (en) | 1996-04-19 | 1997-11-12 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| CA2283299A1 (en) | 1997-03-07 | 1998-09-11 | Human Genome Sciences, Inc. | 186 human secreted proteins |
| JP4486187B2 (ja) * | 1998-10-27 | 2010-06-23 | 武田薬品工業株式会社 | 新規ｇ蛋白質共役型レセプター蛋白質、そのｄｎａおよびそのリガンド |
| US6528054B1 (en) | 1998-12-28 | 2003-03-04 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of breast cancer |
| HK1047045A1 (zh) | 1999-06-28 | 2003-02-07 | Abbott Gmbh & Co. Kg | 預防腫瘤生長的方法 |
| US6638906B1 (en) | 1999-12-13 | 2003-10-28 | Nobex Corporation | Amphiphilic polymers and polypeptide conjugates comprising same |
| WO2001044469A1 (fr) | 1999-12-17 | 2001-06-21 | Takeda Chemical Industries, Ltd. | PROCEDE DE PRODUCTION DE PEPTIDE KiSS-1 |
| HUP0500345A2 (hu) | 2000-03-29 | 2005-07-28 | Corixa Corporation | Készítmények és alkalmazások tüdőrák kezelésére és diagnosztizálására |
| CA2404257A1 (en) | 2000-03-30 | 2001-10-11 | Takeda Chemical Industries, Ltd. | Novel protein, dna thereof and process for producing the same |
| US7834141B1 (en) | 2000-03-31 | 2010-11-16 | Theresa Siler-Khodr | Non-mammalian GnRH analogs and uses thereof in tumor cell growth regulation and cancer therapy |
| RU2311920C2 (ru) | 2000-09-20 | 2007-12-10 | Корикса Корпорейшн | Композиции и способы для лечения и диагностики рака легких |
| JP2003026601A (ja) | 2000-11-29 | 2003-01-29 | Takeda Chem Ind Ltd | 医薬組成物およびその製造法 |
| JP2002320496A (ja) | 2001-02-26 | 2002-11-05 | Takeda Chem Ind Ltd | 新規マウス型ＫｉＳＳ−１レセプタータンパク質およびそのＤＮＡ |
| WO2002085399A1 (fr) | 2001-04-20 | 2002-10-31 | Takeda Chemical Industries, Ltd. | Preparations contenant un peptide |
| US20040185525A1 (en) | 2001-05-17 | 2004-09-23 | Osamu Nishimura | Process for producing peptide |
| ATE360034T1 (de) * | 2001-09-19 | 2007-05-15 | Takeda Pharmaceutical | Antikörper gegen metastin und dessen verwendung zur diagnose von schwangerschaft |
| EP1466976A4 (en) | 2002-01-11 | 2005-11-09 | Takeda Pharmaceutical | PROCESS FOR PREPARING KISS-1 PEPTIDES |
| JP2003300906A (ja) | 2002-04-12 | 2003-10-21 | Daiichi Fine Chemical Co Ltd | がん転移抑制因子の安定化 |
| US20060035875A1 (en) * | 2002-10-09 | 2006-02-16 | Yukimasa Shiotsu | Remedy for hormone-dependent cancer |
| CA2503164A1 (en) | 2002-10-25 | 2004-05-06 | Paradigm Therapeutics Limited | Gpr54 knock-out mammals and screening methods using them |
| JP4804714B2 (ja) | 2002-12-26 | 2011-11-02 | 武田薬品工業株式会社 | メタスチン誘導体およびその用途 |
| AU2003292696A1 (en) * | 2002-12-26 | 2004-08-10 | Takeda Pharmaceutical Company Limited | Metastin derivative and use thereof |
| US6800611B2 (en) * | 2003-01-06 | 2004-10-05 | Takeda Chemical Industries, Ltd. | Metastin derivatives and their use |
| KR100595364B1 (ko) | 2003-02-20 | 2006-07-03 | 재단법인 목암생명공학연구소 | Ｌｋ8 단백질을 유효성분으로 포함하는 항암제 |
| EP1604682A4 (en) | 2003-03-12 | 2009-06-24 | Takeda Chemical Industries Ltd | AGENTS IMPROVING GONADIC FUNCTION |
| EP1464652A1 (en) | 2003-04-02 | 2004-10-06 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | GPR54 receptor agonist and antagonist useful for the treatment of gonadotropin related diseases |
| US20050002935A1 (en) | 2003-04-17 | 2005-01-06 | Vincent Ling | Use of B7-H3 as an immunoregulatory agent |
| CA2523600A1 (en) | 2003-04-28 | 2004-11-11 | Wyeth | Methods utilising g-protein coupled receptor 54 |
| WO2004101747A2 (en) | 2003-05-07 | 2004-11-25 | The General Hospital Corporation | Identification and use of gpr54 and its ligands for reproductive disorders and contraception |
| US20070155803A1 (en) | 2003-05-30 | 2007-07-05 | Prozymex A/S | Protease inhibitors |
| JP4688678B2 (ja) | 2003-11-03 | 2011-05-25 | 北京沙東生物技術有限公司 | 抗癌作用を有する組換えタンパク質、それをコードする遺伝子、及びそれらの使用 |
| WO2005095973A2 (en) | 2004-03-25 | 2005-10-13 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein coupled receptor 54 (gpr54) |
| CA2562676A1 (en) | 2004-04-23 | 2005-12-15 | Applied Research Systems Ars Holding N.V. | Use of gpcr54 ligands for the treatment of infertility |
| MXPA06014206A (es) * | 2004-06-25 | 2007-02-14 | Takeda Pharmaceutical | Derivados de metastina y uso de los mismos. |
| WO2007084211A2 (en) | 2005-11-11 | 2007-07-26 | The General Hospital Corporation | Use of gpr54 ligands for treatment of reproductive disorders, proliferative disorders, and for contraception |
| US20090093615A1 (en) * | 2005-12-22 | 2009-04-09 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| US20090099334A1 (en) * | 2005-12-22 | 2009-04-16 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| TWI386417B (zh) * | 2005-12-22 | 2013-02-21 | Takeda Pharmaceutical | 轉移抑素衍生物及其用途 |
| US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
| JP2009530379A (ja) | 2006-03-20 | 2009-08-27 | メルク エンド カムパニー インコーポレーテッド | ニューロメジンｕ受容体アゴニスト及びその使用 |
| WO2007109857A1 (en) * | 2006-03-28 | 2007-10-04 | Biopharmica Ltd | Agent for the treatment of hormone-dependent disorders and uses thereof |
| TWI404726B (zh) | 2006-10-25 | 2013-08-11 | Takeda Pharmaceutical | 腫瘤轉移抑制素衍生物及其用途 |
| WO2009044918A1 (ja) | 2007-10-05 | 2009-04-09 | Takeda Pharmaceutical Company Limited | ニューロメジンｕ誘導体 |
| EP2277900A4 (en) | 2008-04-24 | 2011-08-03 | Takeda Pharmaceutical | METASTINE DERIVATIVE AND ITS USE |
| EP2340047A1 (en) | 2008-09-19 | 2011-07-06 | Nektar Therapeutics | Polymer conjugates of kiss1 peptides |
-
2007
- 2007-10-23 TW TW096139608A patent/TWI404726B/zh active
- 2007-10-23 JO JOP/2007/0448A patent/JO3048B1/ar active
- 2007-10-24 WO PCT/JP2007/071169 patent/WO2008050897A1/en not_active Ceased
- 2007-10-24 HR HRP20150819TT patent/HRP20150819T1/hr unknown
- 2007-10-24 CL CL200703053A patent/CL2007003053A1/es unknown
- 2007-10-24 AR ARP070104699A patent/AR063367A1/es active IP Right Grant
- 2007-10-24 NZ NZ576375A patent/NZ576375A/en not_active IP Right Cessation
- 2007-10-24 AU AU2007309969A patent/AU2007309969B2/en not_active Ceased
- 2007-10-24 US US11/977,477 patent/US7786083B2/en active Active
- 2007-10-24 ME MEP-2009-130A patent/ME00786B/me unknown
- 2007-10-24 PT PT78309036T patent/PT2081955E/pt unknown
- 2007-10-24 SI SI200731649T patent/SI2081955T1/sl unknown
- 2007-10-24 KR KR1020097010545A patent/KR101424306B1/ko not_active Expired - Fee Related
- 2007-10-24 MY MYPI20091689A patent/MY145975A/en unknown
- 2007-10-24 ES ES07830903.6T patent/ES2539430T3/es active Active
- 2007-10-24 PE PE2007001444A patent/PE20081469A1/es active IP Right Grant
- 2007-10-24 JP JP2009518179A patent/JP2010507565A/ja active Pending
- 2007-10-24 DK DK07830903.6T patent/DK2081955T3/da active
- 2007-10-24 RS RS20150413A patent/RS54083B1/sr unknown
- 2007-10-24 CA CA2667537A patent/CA2667537C/en active Active
- 2007-10-24 US US12/446,142 patent/US8765909B2/en active Active
- 2007-10-24 MX MX2009004148A patent/MX2009004148A/es active IP Right Grant
- 2007-10-24 PL PL07830903T patent/PL2081955T3/pl unknown
- 2007-10-24 EP EP20070830903 patent/EP2081955B1/en active Active
- 2007-10-24 HU HUE07830903A patent/HUE025291T2/en unknown
- 2007-10-24 BR BRPI0717441A patent/BRPI0717441B8/pt not_active IP Right Cessation
- 2007-10-24 GE GEAP200711265A patent/GEP20125568B/en unknown
-
2009
- 2009-04-06 IL IL198046A patent/IL198046A/en active IP Right Grant
- 2009-04-15 TN TNP2009000140A patent/TN2009000140A1/fr unknown
- 2009-04-16 NO NO20091487A patent/NO341584B1/no unknown
- 2009-04-23 EC EC2009009279A patent/ECSP099279A/es unknown
- 2009-05-13 MA MA31868A patent/MA30887B1/fr unknown
- 2009-05-15 CR CR10799A patent/CR10799A/es unknown
-
2013
- 2013-01-11 JP JP2013004011A patent/JP5686825B2/ja not_active Expired - Fee Related
-
2015
- 2015-07-29 CY CY20151100668T patent/CY1116627T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TN2009000140A1 (en) | Metastin derivatives and use thereof | |
| TW200607816A (en) | Metastin derivatives and use thereof | |
| MY151967A (en) | Metastin derivatives and use thereof | |
| MY135222A (en) | Substituted phenylacetamides and their use as glucokinase activators | |
| BRPI0416986A (pt) | preparação farmacêutica compreendendo um anticorpo contra o receptor de egf | |
| JO2932B1 (ar) | مركبات أنسولين ليسبرو مرتبطة بـ peg | |
| EP3409289A3 (en) | Stable antibody containing compositions | |
| EP3165556A3 (en) | Protein-containing adhesives, and manufacture and use thereof | |
| WO2007120557A3 (en) | Method and apparatus of low strengh electric field network-mediated delivery | |
| TNSN06405A1 (en) | Quinazolinone derivatives useful as vanilloid antagonistes | |
| DE602004027288D1 (en) | Thienopyrazole | |
| YU68702A (sh) | Novi lhrh-antagonisti, njihova proizvodnja i upotreba kao leka | |
| UA94774C2 (en) | Metastin derivatives and use thereof | |
| MX337358B (es) | Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos. | |
| UA97236C2 (en) | Metastin derivatives and use thereof | |
| IL151647A0 (en) | Novel lhrh-antagonists, production and use thereof as medicament | |
| UY29859A1 (es) | Derivados de 1-amino-isiquinolina,su preparación y su aplicación terapéutica | |
| MX2009005182A (es) | Derivados de 2-hidroxi-1,3-diamino-propano. | |
| MX2009012599A (es) | Mutantes de vegf-d y su uso. | |
| RU2008115714A (ru) | Ингибитор 8-оксогуанин-днк-гликозилазы человека | |
| DOP2009000092A (es) | Derivados de metastina y sus usos | |
| TW200640945A (en) | Mutants of the fluorescent protein CGFP, and their use | |
| TH97694B (th) | อนุพันธ์เมแทสซิน และการใช้มัน | |
| TN2010000568A1 (en) | Pegylated insulin lispro compounds | |
| WO2004002482A3 (en) | 2-pyridin acetic acid derivatives with antiproliferative activity |